ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

ProQR Therapeutics N.V.NASDAQ: PRQR

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of €2.07M fell 54.3% year over year, behind the -29.2% change in trailing-twelve-month revenue. Sequentially, it fell 55.5% from the prior quarter. Over 3 fiscal years it compounded at +62.0% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of €17.72M (+16.0%) for the fiscal year ending Dec 2026, a step up from the -19.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€2.07M-55.5% QoQ
Last fiscal yearDec 2025
€15.28M-19.2% YoY
LTMMar 2026
€13.44M-29.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.3%+4.5%+58.7 pp
1 year-19.2%+16.0%+35.2 pp
3-year CAGR+62.0%+48.9%-13.1 pp
5-year CAGR+48.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
15.28M EUR
Year-over-year change
-19.2%
4-year CAGR
+83.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -29.2% is the 4th highest of 7, against a peer median of -29.2%.
  • Over three fiscal years its annual growth of +62.0% compares with a peer median of +10.9%.
PRQR Competitors
Revenue for PRQR and competitors
Company Period LTM YoY 3-year CAGR
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$217.78M USD+8.2%-5.3%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$45.35M USD-66.4%-31.1%
EDITEditas Medicine, Inc.LTM Mar 2026$38.69M USD+8.0%+27.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$5.74M USD-96.7%—
IMMPImmutep LimitedFY2025A$5.04M AUD+31.3%+209.4%
MREOMereo BioPharma Group plcLTM Mar 2026$500K USD——
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 USD——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD——
ZURAZura Bio LimitedLTM Mar 2026$0 USD——
Peer median (excluding PRQR) —-29.2%+10.9%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.